Back

Rhelion subsidiary Filament Health to deliver oral comments at FDA psychedelic hearing

Verifying
  • Filament Health will deliver oral comments at an FDA public hearing.
  • The hearing concerns the potential future therapeutic use of psychedelic drugs.
  • Filament Health is a wholly owned subsidiary of Rhelion Life Sciences.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.